Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Stocks

Core PCE Data Has Powell Pleased – May Set Tone For Q2

by March 30, 2024
March 30, 2024
Core PCE Data Has Powell Pleased – May Set Tone For Q2

The Fed’s preferred gauge of inflation was released today and, according to Fed chief Jerome Powell, “it was good,” as there were no ugly surprises. This news could boost the markets, as sticky inflation data has had investors on edge amid interest rates that have remained relatively high. The stock and bond markets were of course closed today, however, so we won’t see a response from traders until next week.

Overall, we’re heading into next week on good terms, with the Dow, Nasdaq and the S&P 500 at new highs with small-cap stocks in an uptrend after posting an impressive 2.5%. In other positive news, we’re continuing to see a broadening out of participation well beyond the Magnificent Seven stocks which dominated last year’s top performance lists.

Daily Chart of S&P 500 Index

With so much bullish behavior, it may be difficult to determine where to focus your efforts so that you can outperform these strong markets. From my work, honing in on companies that have strong growth outlooks will always pay off, particularly during a bull market phase such as now.

Many of these faster-growing companies — particularly in Technology — have seen impressive returns year-to-date already, with consolidation phases needed before another leg up. Instead, I’m looking for stocks in areas such as Healthcare, which have entered a new uptrend after trending sideways over the past 3 weeks. While normally viewed as a defensive area of the markets, there’s plenty of fast-growing companies amid the development of new drugs and medical products.

Daily Chart of Healthcare Sector (XLV)

A prime example is Eli Lilly (LLY) which was added to my MEM Edge Report’s suggested holdings list in early January. In addition to the company’s popular weight loss drug Zepbound, which was approved late last year, The company is on track to see their Alzheimer’s drug approved next quarter.

LLY has been trending upward in a tight trading range in anticipation of this FDA approval, and this recent period of consolidation has allowed the stock to recover from an overbought condition during February. A close above its recent high of $800, coupled with a bullish MACD crossover, would put the stock into a strong buy zone.

Daily Chart of Eli Lilly (LLY)

Other newer areas are also beginning to emerge, and if you’d like to be alerted to new buy ideas in these areas, use this link here to trial my twice weekly MEM Edge report. You’ll also receive in-depth information regarding broader market conditions as well as sector rotation that’s taking place and why. I hope you’ll take advantage of this offer!

Warmly,

Mary Ellen McGonagle

MEM Investment Research

0
FacebookTwitterGoogle +Pinterest
previous post
These Breadth Charts PROVE How Strong This Bull Market Is
next post
Kia recalling 427,000 Telluride SUVs because they might roll away while parked

Related Posts

Powerful Entry Strategy Using One Moving Average

May 16, 2024

EB Weekly Market Report – Monday, November 20,...

November 20, 2023

The Worst Month of the Year is Behind...

September 30, 2023

Sector Spotlight: S&P 500 – Consumer Discretionary Sector...

November 21, 2023

Volatility Ahead: What Investors Need to Know Right...

April 1, 2025

Looking At a Perfect Pullback Opportunity

October 13, 2023

Emerging Stocks to Watch – Breakouts, Momentum &...

May 21, 2025

Your Burning Questions, Answered: FATE of TESLA &...

September 30, 2023

Exponential vs. Simple: This is the Moving Average...

October 10, 2023

What Can the VIX Reveal To Us In...

November 3, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

    • Week Ahead: NIFTY Stays In A Defined Range; Moving Past This Level Crucial For Resumption Of Upmove

    • Editor’s Picks: Gold Faces Bumpy Week on Trade Tensions, Platinum Stages Breakout

    • Run Your Stock Portfolio Like a Pro Sports Team

    • Leadership Rotation Could Confirm Corrective Phase

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

    Categories

    • Business (1,223)
    • Investing (2,504)
    • Politics (3,699)
    • Stocks (1,616)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved